Chronic Renal Failure Clinical Trial
— MEDIAOfficial title:
Telemonitoring Impact by the ApTelecare Software in Dialysis Patient
NCT number | NCT03927300 |
Other study ID # | KM-00153 |
Secondary ID | |
Status | Completed |
Phase | |
First received | |
Last updated | |
Start date | July 17, 2019 |
Est. completion date | December 11, 2019 |
Verified date | March 2020 |
Source | Tmm Software |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational [Patient Registry] |
The investigators proposed to conduct a retrospective study to evaluate the impact of the implementation of apTeleCare software on the management of dialysis patients at home in terms of the number and duration of hospitalizations. For this purpose, the investigators will compare patients' data over a 2-year interval before the introduction of Telemonitoring (January 2012 and December 2013 inclusive - Group 1) with patients data who have benefited from this application (between August 2016 and July 2018).
Status | Completed |
Enrollment | 72 |
Est. completion date | December 11, 2019 |
Est. primary completion date | July 17, 2019 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Adult patients (= 18 years) with no age limit; - Patients receiving peritoneal dialysis on the investigation center between 2012 and 2014 (Group1) and between 2016 and 2018 (Group 2); - Patient information in this retrospective study; Exclusion Criteria: - Patients who have started a peritoneal dialysis program before the periods of investigation; - Patients who have been equipped with apTeleCare during the dialysis program; - Subject under guardianship, curators or safeguard of justice; - Patient not affiliated to a French social protection; |
Country | Name | City | State |
---|---|---|---|
France | Matthieu Merlot | Montpellier |
Lead Sponsor | Collaborator |
---|---|
Tmm Software | Centre Hospitalier de Vichy |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Cumulative duration (on retrospective two years of follow-up) of the unscheduled hospitalizations between the two patient groups. | up to two years. | ||
Primary | Cumulative duration (on retrospective two years of follow-up) of the scheduled hospitalizations between the two patient groups. | up to two years. | ||
Secondary | Total length of hospitalisation | For both groups. Every two months (follow-up visit) on a retrospective period of two years, the outcome 2 will be measured. The study duration will be of 5 months | ||
Secondary | Number of events of cardiovascular complications | For both groups. Every two months (follow-up visit) on a retrospective period of two years. The study duration will be of 5 months | ||
Secondary | Mortality rate | For both groups. At the end of this retrospective study (Study Period of 5 months). | ||
Secondary | Rate of peritoneal infections | For both groups. At the end of this retrospective study.(Study Period of 5 months). | ||
Secondary | Number of patient exit technique except death | For example transplant, hemodialysis | For both groups. At the end of this retrospective study. (Study Period of 5 months). | |
Secondary | Charlson score : Comorbidity index | This scale measure the comorbidity symptoms of patients at the beginning of the care by the physician. The minimum score will be "0" and the maximum will be 39. Its validation is based on a prediction of health French insurance, as well as on several clinical areas such as oncology or nephrology. |
baseline |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT02565459 -
MSC and Kidney Transplant Tolerance (Phase A)
|
Phase 1 | |
Recruiting |
NCT02356419 -
rESP Medication With a Single Intravenous Administration and Dose Escalation to Explore the Tolerability ,Safety and Pharmacokinetic Characteristics
|
Phase 1 | |
Recruiting |
NCT01876017 -
Safety and Efficacy of BMMNC in Patients With Chronic Renal Failure
|
Phase 1/Phase 2 | |
Withdrawn |
NCT03019159 -
Assessment of a Follow-up With Tele-consulting for Patients With Renal Failure Under Peritoneal Dialysis
|
N/A | |
Completed |
NCT02047006 -
Dose-finding of Rivaroxaban in Hemodialysis
|
Phase 4 | |
Completed |
NCT01617824 -
Rapid Effects Linagliptin on Monocyte Polarization and Endothelial Progenitor Cells in Type 2 Diabetes
|
Phase 4 | |
Completed |
NCT00597753 -
Safety & Efficacy of Peginesatide for Maintenance Treatment of Anemia in Participants With Chronic Kidney Disease on Hemodialysis
|
Phase 3 | |
Completed |
NCT00828776 -
Pharmacodynamics and Non-Clinical Inferiority of Heparin Sodium (Cristália) Compared With the Product Liquemine (Roche) in Chronic Renal Failure
|
Phase 2/Phase 3 | |
Terminated |
NCT00372489 -
Extension Study to Evaluate Safety and Tolerability of Peginesatide for Long-Term Treatment of Anemia in Participants With CKD
|
Phase 2 | |
Completed |
NCT00379899 -
ADVANCE: Study to Evaluate Cinacalcet Plus Low Dose Vitamin D on Vascular Calcification in Subjects With Chronic Kidney Disease Receiving Hemodialysis
|
Phase 4 | |
Completed |
NCT00228436 -
Safety, PD & PK of Multiple Doses of Peginesatide for Anemia in Chronic Kidney Disease Patients
|
Phase 2 | |
Completed |
NCT03772171 -
Estimate for Dietary Intakes and Hemodialysis Patients
|
||
Recruiting |
NCT02586402 -
Safety & Efficacy of Pegolsihematide for Treatment of Anemia in Participants on Dialysis
|
Phase 2 | |
Completed |
NCT01879618 -
Use Of Fragmin In Hemodialysis
|
Phase 3 | |
Not yet recruiting |
NCT01346215 -
Study of Clinical Non-inferiority of Actparin® (Laboratorio Bergamo) Compared to Heparin Sodium (APP Pharmaceuticals), in Patients With Chronic Renal Failure
|
Phase 3 | |
Completed |
NCT01220843 -
FGF23 Reduction : Efficacy of a New Phosphate Binder in CHronic Kidney Disease
|
Phase 3 | |
Completed |
NCT01111630 -
Study of Erythropoietin (EPO) Administration Schedule
|
Phase 4 | |
Completed |
NCT00742716 -
Safety Study of CTA018 Injection to Treat Stage 5 Chronic Kidney Disease
|
Phase 2 | |
Completed |
NCT00597584 -
Safety & Efficacy of Peginesatide for Maintenance Treatment of Anemia in Participants With Chronic Kidney Disease on Hemodialysis
|
Phase 3 | |
Completed |
NCT00598273 -
Safety & Efficacy of Peginesatide for the Treatment of Anemia in Participants With Chronic Renal Failure Not on Dialysis
|
Phase 3 |